Evidence map›Paper›PMID 40755438›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Nanoshield-Assisted Viral Gene Therapy with Induction of Non-Apoptotic Cell Death and Durable Antitumor Immunity.

Soo-Hwan Lee, Yunkyeong Cho, Seunghwan Bang, Daeun Sung, Jahyun Koo, Seoyoung Kim, Youngil Koh, Hojun Kim, Hyojin Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Soo-Hwan LeeBiomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Yunkyeong ChoBiomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Seunghwan BangDivision of Biomedical Science and Technology, KIST School, Korea University of Science and Technology, Seoul, 02792, Republic of Korea.
Daeun SungSchool of Biomedical Engineering, Korea University, Seoul, 02841, Republic of Korea.
Jahyun KooSchool of Biomedical Engineering, Korea University, Seoul, 02841, Republic of Korea.
Seoyoung KimBiomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Youngil KohDepartment of Internal Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
Hojun KimDivision of Biomedical Science and Technology, KIST School, Korea University of Science and Technology, Seoul, 02792, Republic of Korea.
Hyojin LeeBiomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.ORCID https://orcid.org/0000-0001-6367-9485

Funding

Korea Institute of Science and Technology 2E33781Ministry of Health & Welfare, Republic of Korea RS-2024-00438476National Research Foundation of Korea RS-2024-00403376
6 · The paper itself

Abstract

Non-apoptotic cell death have emerged as promising strategies to overcome apoptotic resistance in cancer therapy. We suggest a hybrid gene delivery platform integrating adeno-associated virus (AAV)-mediated expression of receptor-interacting kinase 3(RIPK3) with manganese dioxide-polyethyleneimine (MnO

Indexed as

DependovirusGenetic TherapyNeoplasmsAnimalsApoptosisCell DeathCell Line, TumorGene Transfer TechniquesHumansManganese CompoundsMiceOxidesPolyethyleneimineTumor MicroenvironmentManganese Compoundsmanganese dioxideOxidesPolyethyleneimineadeno‐associated virus (AAV)cancer immune therapymanganese‐nanoshieldnecroptosisreceptor‐interacting kinase 3 (RIPK3)

Identifiers

PMID40755438
PMCPMC12591101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.